Loulwah Alothman

Dr. Loulwah Alothman

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LALoulwah Alothman
Loulwah Alothman
EHEmad Hadlaq
Emad Hadlaq
AAAsma Abdullatif Alhussain
Asma Abdullatif Alhussain
AAAlwaleed Abdullah Alabdulkarim
Alwaleed Abdullah Alabdulkarim
Youssef SariYoussef Sari
Youssef Sari
SAShakir AlSharari
Shakir AlSharari
Background/Objectives: Neuropathic pain is challenging to treat, often resistant to current therapies, and associated with significant side effects. Pregabalin, an anticonvulsant that modulates calcium channels, is effective but can impair mental and motor functions, especially in older patients. To improve patient outcomes, reducing the doses of pregabalin and combining it with other drugs targeting different neuropathic pain mechanisms may be beneficial. TNF-α blockers such as etanercept have shown potential in addressing neuropathic pain by affecting sodium channels, synaptic transmission, and neuroinflammation. This study evaluates the efficacy and safety of combining low doses of etanercept and pregabalin in allodynia and nociceptive tests. Materials and Methods: Male C57/BL6 mice underwent chronic constriction injury (CCI) of the sciatic nerve to induce neuropathic pain. They were divided into seven groups: sham control, CCI control, low and high doses of pregabalin, low and high doses of etanercept, and a combination of low doses of both drugs. Behavioral tests, including von Frey, hot-plate, and rotarod tests, were used to assess pain responses and motor activity. Results: The results indicated that a high dose of pregabalin significantly reduced mechanical allodynia and thermal hyperalgesia but impaired motor function. Conversely, low doses of etanercept alone had no significant effect. However, the combination of low doses of etanercept (20 mg/kg) and pregabalin (5 mg/kg) effectively alleviated pain without compromising locomotor activity. Conclusions: These results suggest a novel therapeutic strategy for neuropathic pain, enhancing analgesic efficacy while minimizing adverse effects.

Verified
Journal Article
Open access
PDF file
YHYousef Hawsawi
Yousef Hawsawi
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
SAShouq Fahad Alghannam
Shouq Fahad Alghannam
HAHala Aldahshan
Hala Aldahshan
LALoulwah Alothman
Loulwah Alothman
SASarah S. Alotaibi
Sarah S. Alotaibi
Microgravity research has emerged as a rapidly evolving field at the intersection of space medicine, genomics, biotechnology, and precision medicine. Exposure to the space environment induces complex physiological and molecular adaptations that affect multiple biological systems, including immune regulation, metabolism, musculoskeletal function, and gene expression. Recent advances in genomics, multi-omics technologies, artificial intelligence, and bioengineering have substantially improved our understanding of biological adaptation to spaceflight and expanded opportunities for translational biomedical research. This review summarizes recent advances in genetic and biomedical research under microgravity conditions, with particular emphasis on molecular mechanisms, omics technologies, genome editing, microbiome research, regenerative medicine, and personalized healthcare approaches. Major experimental platforms, landmark spaceflight studies, and translational applications in infectious diseases, cancer biology, aging, tissue engineering, and pharmaceutical development are discussed. The review also highlights Saudi Arabia’s emerging contributions to genomic medicine and space biosciences through initiatives such as the Saudi Human Genome Program, the Saudi Pangenome Project, the Saudi Space Agency, and the BioGravity Initiative. Recent Saudi participation in human spaceflight and microgravity-associated biomedical research is discussed within the context of Vision 2030 and national investments in biotechnology and precision medicine. Collectively, advances in microgravity research are expected to contribute to the advancement of precision medicine and facilitate the development of innovative diagnostic and therapeutic strategies with significant implications for both human space exploration and terrestrial healthcare.

13 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LALoulwah Alothman
Loulwah Alothman
AAAlaa Alnoor Alnoor Alameen
Alaa Alnoor Alnoor Alameen
MAMohammed M Alshehri
Mohammed M Alshehri
AAAbdullah Mohamed Abdullah
Abdullah Mohamed Abdullah
HAHala Aldahshan
Hala Aldahshan
MEMougina K Eltahir
Mougina K Eltahir
Background/Objectives: Myocardial infarction (MI) remains a major therapeutic challenge, and the molecular targets potentially associated with the cardiovascular activity of Adansonia digitata phytochemicals remain incompletely characterized. This study integrated phytochemical, transcriptomic, disease-gene, network, and structural evidence to prioritize candidate phytochemical–MI target associations. Methods: Ten polyphenols were selected from published LC-MS/QTOF data. Targets predicted using SwissTargetPrediction and PharmMapper were integrated with MI-associated evidence from the GSE66360 (circulating endothelial cell), GSE325257 (cardiac targeted gene-expression), and DisGeNET. An initial composite analysis generated a 19-gene discovery module for network and structural prioritization. A complementary source-resolved sensitivity analysis independently evaluated the three MI evidence sources. Selected interactions were examined by molecular docking, 200 ns molecular dynamics simulations, and MM/PBSA binding free-energy estimation. Results: Sensitivity analysis identified 189 genes supported by at least two MI evidence sources, including 21 predicted Adansonia digitata targets. Four genes (GSK3B, NOS3, SOD2, and TGFBR1) were shared between the 19-gene discovery and 21-gene sensitivity modules. Gene Ontology analysis identified 36 significantly overrepresented biological-process terms (FDR < 0.05). Docking supported the selection of chlorogenic acid and rutin for simulation with MMP2 and NOS3. MM/PBSA calculations indicated that chlorogenic acid exhibited more favorable estimated binding energies compared to rutin, especially in the case of MMP2. However, these differences were not statistically validated. Conclusions: The complementary integration strategies prioritized candidate Adansonia digitata phytochemicals and MI-associated targets and generated testable hypotheses for further investigation. These computational findings are hypothesis-generating and require experimental validation of target engagement, biological activity, pharmacokinetics, and efficacy in MI models.

Verified
Journal Article
Open access
PDF file
LALoulwah Alothman
Loulwah Alothman
AAAlaa Alnoor Alnoor Alameen
Alaa Alnoor Alnoor Alameen
MEMougina K Eltahir
Mougina K Eltahir
Oral lichen planus (LP) is widely described as molecularly distinct from cutaneous LP, yet most supporting transcriptomic evidence compares mucosal epithelium with full-thickness skin. We reanalysed four public microarray series covering oral, genital and cutaneous LP (101 arrays) with matched microRNA arrays, using covariate-adjusted models, meta-analysis, cross-platform integration, a within-platform site-by-disease interaction model, pathway and deconvolution scoring and a test of experimentally supported microRNA–target interactions. Eighty-five genes were differentially expressed at both discovery sites, 83 concordantly, dominated by cornified-envelope and keratinisation genes; BPIFC, CDSN and WFDC12 replicated in all four cohorts. A 52-gene barrier score separated lesional from control tissue in the discovery and genital cohorts (AUC 0.98–1.00, partly in-sample), and panels derived at one LP site transferred across study, platform and site (AUC 0.95–0.99), but the score did not reach significance in the only fully independent oral cohort (AUC 0.76, p = 0.13). In comparator series, the programme was also induced in psoriasis and partly in cutaneous lupus, but not in atopic dermatitis, eosinophilic oesophagitis or periodontitis, so it is shared rather than LP-specific. Interferon and MYC-target activity and several immune populations were higher in cutaneous LP, but an epithelial:immune compartment proxy showed that cutaneous biopsies were full-thickness whereas mucosal biopsies were epithelium-only, confounding this contrast. Within one platform, 292 genes showed an oral-versus-genital interaction. Neither miR-20a-5p nor miR-34a-5p tracked barrier expression, and across 222,203 supported microRNA–target pair correlations were predominantly positive rather than inverse. Across LP sites, a reproducible epithelial barrier programme is the most consistent shared feature, although it is not specific to LP and its transfer to independent cohorts remains provisional; reported immune divergence cannot be separated from the biopsy compartment.